Tracers / [90Y]Y-90-DTPA-rituximab
[90Y]Y-90-DTPA-rituximab
Also written as Y-90-DTPA-rituximab; Y-90-DTPA-Rituximab
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- DTPA-conjugated anti-CD20 monoclonal antibody (rituximab) immunoconjugate
- Target / mechanism
- CD20 PMID 27980563
- Clinical application
- Non-Hodgkin's lymphoma (NHL) radioimmunotherapy/imaging PMID 27980563
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | p-SCN-Bn-DTPA Macrocyclics | 27980563 2016 Iran J Pharm Res |
Need this precursor?We can point you to suppliers for [90Y]Y-90-DTPA-rituximab, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 27980563: 'p-SCN-Bn-DTPA [2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid]'.